X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (48381) 48381
Publication (4958) 4958
Book Review (1134) 1134
Book Chapter (338) 338
Conference Proceeding (89) 89
Dissertation (36) 36
Magazine Article (13) 13
Newspaper Article (12) 12
Trade Publication Article (8) 8
Streaming Video (7) 7
Paper (6) 6
Data Set (4) 4
Presentation (3) 3
Newsletter (2) 2
Transcript (2) 2
Book / eBook (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36339) 36339
index medicus (32324) 32324
oncology (22885) 22885
female (17052) 17052
cancer (15025) 15025
male (14058) 14058
chemotherapy (13564) 13564
middle aged (12206) 12206
aged (10949) 10949
adult (10072) 10072
care and treatment (9189) 9189
treatment outcome (8948) 8948
pharmacology & pharmacy (7345) 7345
phase-ii (7231) 7231
medicine & public health (7191) 7191
research (6701) 6701
animals (6422) 6422
antineoplastic combined chemotherapy protocols - therapeutic use (6328) 6328
antineoplastic agents - therapeutic use (6273) 6273
clinical trials (6108) 6108
phase-ii trial (5846) 5846
analysis (5779) 5779
phase-iii (5094) 5094
health aspects (5081) 5081
phase-iii trial (4860) 4860
metastasis (4816) 4816
drug therapy (4785) 4785
prognosis (4694) 4694
tumors (4617) 4617
survival (4587) 4587
therapy (4511) 4511
aged, 80 and over (4289) 4289
hematology, oncology and palliative medicine (4212) 4212
surgery (4045) 4045
double-blind (4025) 4025
radiotherapy (3977) 3977
hematology (3973) 3973
cancer therapies (3834) 3834
patients (3810) 3810
trial (3530) 3530
phase-i (3430) 3430
retrospective studies (3413) 3413
disease-free survival (3368) 3368
neoplasm staging (3361) 3361
cisplatin (3267) 3267
clinical trials as topic (2994) 2994
studies (2958) 2958
breast cancer (2949) 2949
clinical trials, phase iii as topic (2928) 2928
immunotherapy (2907) 2907
antineoplastic agents (2819) 2819
randomized controlled trials as topic (2801) 2801
carcinoma (2795) 2795
article (2710) 2710
survival analysis (2689) 2689
open-label (2653) 2653
antimitotic agents (2645) 2645
combined modality therapy (2640) 2640
medical research (2636) 2636
survival rate (2581) 2581
cancer research (2538) 2538
antineoplastic combined chemotherapy protocols - adverse effects (2518) 2518
lung neoplasms - drug therapy (2479) 2479
pharmacology/toxicology (2453) 2453
risk factors (2440) 2440
neoplasms - drug therapy (2408) 2408
lung cancer (2376) 2376
review (2375) 2375
medicine (2347) 2347
efficacy (2346) 2346
development and progression (2326) 2326
randomized-trial (2318) 2318
bevacizumab (2316) 2316
combination (2309) 2309
internal medicine (2260) 2260
medicine, research & experimental (2259) 2259
antineoplastic agents - pharmacology (2258) 2258
young adult (2240) 2240
toxicity (2239) 2239
antineoplastic agents - adverse effects (2221) 2221
patient outcomes (2210) 2210
1st-line treatment (2198) 2198
paclitaxel (2194) 2194
antineoplastic agents - administration & dosage (2178) 2178
mutation (2160) 2160
usage (2113) 2113
safety (2089) 2089
dose-response relationship, drug (2070) 2070
cell lung-cancer (2065) 2065
apoptosis (2050) 2050
immunology (2047) 2047
gemcitabine (2037) 2037
medical prognosis (2030) 2030
radiation-therapy (2026) 2026
breast neoplasms - drug therapy (1996) 1996
colorectal cancer (1981) 1981
carcinoma, non-small-cell lung - drug therapy (1969) 1969
adolescent (1967) 1967
docetaxel (1916) 1916
antibodies, monoclonal - therapeutic use (1914) 1914
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (48683) 48683
Japanese (99) 99
German (26) 26
French (17) 17
Polish (13) 13
Chinese (11) 11
Dutch (1) 1
Italian (1) 1
Slovenian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2018, Volume 20, Issue 3, pp. 620 - 628
Aim To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium‐glucose co‐transporter‐2 inhibitor, in patients with type 2 diabetes... 
antidiabetic drug | type 2 diabetes | SGLT2 inhibitor | dapagliflozin | METFORMIN | METAANALYSIS | EFFICACY | SGLT2 INHIBITORS | KETOACIDOSIS | CANAGLIFLOZIN | TOLERABILITY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | BONE | EMPAGLIFLOZIN | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Humans | Middle Aged | Blood Volume - physiology | Male | Treatment Outcome | Clinical Trials, Phase III as Topic | Glomerular Filtration Rate - drug effects | Reproductive Tract Infections - chemically induced | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Fractures, Spontaneous - chemically induced | Adult | Female | Aged | Amputation - statistics & numerical data | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Glucosides - adverse effects | Clinical Trials, Phase II as Topic | Diabetic Ketoacidosis - chemically induced | Type 2 diabetes | Clinical trials | Complications and side effects | Urinary tract infections | Hypoglycemic agents | Glucose transporter | Creatinine | Renal function | Diabetes mellitus | Data processing | Urinary tract | Ketonuria | Hypoglycemia | Fractures | Sodium | Ketoacidosis | Amputation | Diabetes | Acidosis | Diabetes mellitus (non-insulin dependent) | Metabolic acidosis | Original
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2018, Volume 20, Issue 9, pp. 2200 - 2209
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2169 - 2176
Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or... 
THERAPY | ANTIANDROGEN | ONCOLOGY | RESISTANCE | PHASE-II | RADICAL PROSTATECTOMY | INCREASED SURVIVAL | CANCER | CHEMOTHERAPY | PROGRESSION | ABIRATERONE | Neoplasm, Residual - pathology | Phenylthiohydantoin - adverse effects | Prostatic Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Combined Modality Therapy | Neoplasm, Residual - blood | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Phenylthiohydantoin - administration & dosage | Receptors, Androgen - genetics | Leuprolide - administration & dosage | Neoadjuvant Therapy - adverse effects | Prostatic Neoplasms - blood | Prostatectomy | Aged | Neoplasm, Residual - chemically induced | Dutasteride - administration & dosage | Prostatic Neoplasms - drug therapy | Therapy | Risk groups | Health risks | Minimal residual disease | Patients | Anticancer properties | Testosterone | Signaling | Dihydrotestosterone | Androgens | Flutamide | Experimental design | Luteinizing hormone | Luteinizing hormone-releasing hormone | Antitumor activity | Prostate cancer | Prostate | Cancer | dutasteride | neoadjuvant | NEW MOLECULAR TARGETS | THERAPEUTICS: Cellular responses to anticancer drugs | CL01 PHASE I – III CLINICAL TRIALS: Phase I–III Trials_Genitourinary cancers: prostate | ET02 MECHANISMS OF DRUG ACTION | enzalutamide
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2006, Volume 12, Issue 11, pp. 3381 - 3388
Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal... 
Phase I-III Clinical Trials | Lung Cancer: New Targets | Molecular Oncology | Growth factor receptors and other surface molecules as targets for therapy | GROWTH-FACTOR RECEPTOR | GEFITINIB | THERAPY | ONCOLOGY | TYROSINE KINASE | MAJOR URINARY METABOLITE | CHEMOPREVENTION | MUTATIONS | CYCLOOXYGENASE-2 INHIBITOR | PROSTAGLANDIN E-2 | EGF RECEPTOR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Follow-Up Studies | Antineoplastic Combined Chemotherapy Protocols - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Gene Expression Profiling | Dose-Response Relationship, Drug | Sulfonamides - blood | Cyclooxygenase 2 - genetics | Pyrazoles - blood | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Drug Therapy, Combination | Pyrazoles - adverse effects | Drug Administration Schedule | Treatment Outcome | Celecoxib | Reverse Transcriptase Polymerase Chain Reaction | Disease Progression | Quinazolines - blood | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Sulfonamides - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Sulfonamides - administration & dosage | Cohort Studies
Journal Article